Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:3910131rdf:typepubmed:Citationlld:pubmed
pubmed-article:3910131lifeskim:mentionsumls-concept:C0028754lld:lifeskim
pubmed-article:3910131lifeskim:mentionsumls-concept:C0026809lld:lifeskim
pubmed-article:3910131lifeskim:mentionsumls-concept:C0124026lld:lifeskim
pubmed-article:3910131pubmed:issue9lld:pubmed
pubmed-article:3910131pubmed:dateCreated1986-3-5lld:pubmed
pubmed-article:3910131pubmed:abstractTextA quantitative method for circulating islet cell surface antibodies (ICSA), based on the binding of 125I-protein A to insulin-producing RINm5F cells, was used to evaluate ICSA in plasma of 4- to 40-week-old Aston obese hyperglycaemic (ob/ob) mice and normal control (+/+) mice. RINm5F cells bound 2502 +/- 1196 c.p.m. 125I-protein A per 10(5) cells (mean +/- S.D., n = 54) after incubation with +/+ plasma. ICSA positive plasma (defined as 125I-protein A binding, mean +/- 2 S.D. of +/+ plasma) was detected in 3 out of 54 +/+ mice and 3 out of 54 ob/ob mice. ICSA were not observed in ob/ob mice before the onset of diabetes (7 weeks of age), but were detected at 9, 20 and 40 weeks. At 20 weeks 125I-protein A binding produced by ob/ob plasma was 35% greater than +/+ plasma (P less than 0.05). The low occurrence of ICSA in ob/ob mice (6%) suggests that factors other than ICSA are responsible for B-cell dysfunction and eventual islet degeneration observed in Aston ob/ob mice.lld:pubmed
pubmed-article:3910131pubmed:languageenglld:pubmed
pubmed-article:3910131pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3910131pubmed:citationSubsetIMlld:pubmed
pubmed-article:3910131pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3910131pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3910131pubmed:statusMEDLINElld:pubmed
pubmed-article:3910131pubmed:monthSeplld:pubmed
pubmed-article:3910131pubmed:issn0144-8463lld:pubmed
pubmed-article:3910131pubmed:authorpubmed-author:BoneA JAJlld:pubmed
pubmed-article:3910131pubmed:authorpubmed-author:BaileyC JCJlld:pubmed
pubmed-article:3910131pubmed:authorpubmed-author:FlattP RPRlld:pubmed
pubmed-article:3910131pubmed:issnTypePrintlld:pubmed
pubmed-article:3910131pubmed:volume5lld:pubmed
pubmed-article:3910131pubmed:ownerNLMlld:pubmed
pubmed-article:3910131pubmed:authorsCompleteYlld:pubmed
pubmed-article:3910131pubmed:pagination715-20lld:pubmed
pubmed-article:3910131pubmed:dateRevised2003-11-14lld:pubmed
pubmed-article:3910131pubmed:meshHeadingpubmed-meshheading:3910131-...lld:pubmed
pubmed-article:3910131pubmed:meshHeadingpubmed-meshheading:3910131-...lld:pubmed
pubmed-article:3910131pubmed:meshHeadingpubmed-meshheading:3910131-...lld:pubmed
pubmed-article:3910131pubmed:meshHeadingpubmed-meshheading:3910131-...lld:pubmed
pubmed-article:3910131pubmed:meshHeadingpubmed-meshheading:3910131-...lld:pubmed
pubmed-article:3910131pubmed:meshHeadingpubmed-meshheading:3910131-...lld:pubmed
pubmed-article:3910131pubmed:meshHeadingpubmed-meshheading:3910131-...lld:pubmed
pubmed-article:3910131pubmed:meshHeadingpubmed-meshheading:3910131-...lld:pubmed
pubmed-article:3910131pubmed:meshHeadingpubmed-meshheading:3910131-...lld:pubmed
pubmed-article:3910131pubmed:year1985lld:pubmed
pubmed-article:3910131pubmed:articleTitleIslet cell surface antibodies in genetically obese hyperglycaemic (ob/ob) mice.lld:pubmed
pubmed-article:3910131pubmed:publicationTypeJournal Articlelld:pubmed